TS-011

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H14ClN3O2
Molecular Weight	255.701
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O\N=C\NC1=CC(Cl)=C(C=C1)N2CCOCC2

InChI

InChIKey=ZTXADXBIGLLOFX-UHFFFAOYSA-N

InChI=1S/C11H14ClN3O2/c12-10-7-9(13-8-14-16)1-2-11(10)15-3-5-17-6-4-15/h1-2,7-8,16H,3-6H2,(H,13,14)

HIDE SMILES / InChI

Molecular Formula	C11H14ClN3O2
Molecular Weight	255.701
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 4A11 1 Target ID: Q02928 Gene ID: 1579.0 Gene Symbol: CYP4A11 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15831442 \| https://www.ncbi.nlm.nih.gov/pubmed/29277328	Inhibitor 8297

PubMed

Title	Date	PubMed
Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.	2005 Jul	15831442

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:15:05 UTC 2023` Edited by `admin` on `Sat Dec 16 10:15:05 UTC 2023`
Record UNII	FP24MFJ1RM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TS-011

Code

English

N-(3-CHLORO-4-MORPHOLIN-4-YL) PHENYL-N-HYDROXYIMIDO FORMAMIDE

Common Name

English

N-(3-CHLORO-4-MORPHOLINO-PHENYL)-N'-HYDROXY-FORMAMIDINE

Systematic Name

English

N-(3-CHLORO-4-(4-MORPHOLINYL)PHENYL)-N'-HYDROXYMETHANIMIDAMIDE

Systematic Name

English

METHANIMIDAMIDE, N-(3-CHLORO-4-(4-MORPHOLINYL)PHENYL)-N'-HYDROXY-

Systematic Name

English

Code System Code Type Description

FDA UNII

FP24MFJ1RM

Created by admin on Sat Dec 16 10:15:05 UTC 2023 , Edited by admin on Sat Dec 16 10:15:05 UTC 2023

PRIMARY

PUBCHEM

9816527

Created by admin on Sat Dec 16 10:15:05 UTC 2023 , Edited by admin on Sat Dec 16 10:15:05 UTC 2023

PRIMARY

EPA CompTox

DTXSID00431234

Created by admin on Sat Dec 16 10:15:05 UTC 2023 , Edited by admin on Sat Dec 16 10:15:05 UTC 2023

PRIMARY

CAS

339071-18-0

Created by admin on Sat Dec 16 10:15:05 UTC 2023 , Edited by admin on Sat Dec 16 10:15:05 UTC 2023

PRIMARY

Related Record Type Details


					YO7TYY4C53

CYTOCHROME P450 4A11

TARGET -> INHIBITOR


					0PRP3JCL1P

CYTOCHROME P450 4F3

TARGET -> INHIBITOR

Amount:


					4PBV944KVV

CYTOCHROME P450 4F2

TARGET -> INHIBITOR

Related Record Type Details


					FP24MFJ1RM

TS-011

ACTIVE MOIETY

Comments:

We found that TS-011 significantly inhibited both the decrease and the increase in the blood flow velocities in the peri-infarct microvessels seen in the vehicle-treated mice after reperfusion. In addition, TS-011 significantly inhibited the reduction in the microvascular perfusion area after reperfusion, compared with the vehicle-treated group. Moreover, TS-011 significantly reduced the infarct volume by 40% at 72 h after middle cerebral artery occlusion.


					FP24MFJ1RM

TS-011

ACTIVE MOIETY

Comments:

TS-011 inhibited the synthesis of 20-HETE by human renal microsomes and recombinant CYP4A11 and 4F2, 4F3A, and 4F3B enzymes with IC50 values around 10 to 50 nM. It had no effect on the activities of CYP1A, 2C9, 2C19, 2D6, or 3A4 enzymes. TS-011 inhibited the synthesis of 20-HETE by rat renal microsomes with an IC50 of 9.19 nM, and it had no effect on epoxygenase activity at a concentration of 100 microM. TS-011 (0.01-1 mg/kg i.v.) reversed the fall in cerebral blood flow and the increase in 20-HETE levels in the cerebrospinal fluid of rats after SAH.